The company will use the funds to develop and refine proprietary algorithms for identifying more complex variants including translocations and inversions.
The firm said it saw a robust contribution in the first half of the year from its Dharmacon business and noted that it increased its reach into the US market.
British software firm Congenica is partnering with Hong Kong's Digital China Health Technologies to expand its clinical genomics interpretation business in China.
The appropriations package would boost the NIH's fiscal 2019 budget to $39.1 billion, and earmarks money for programs such as the All of Us initiative.
The survey, conducted by SeraCare Life Sciences and GenomeWeb, asked more than 150 individuals working on clinical NGS about their quality control practices.
The planned program is part of beta test of Repositive’s Cancer Models platform which connects biopharmaceutical companies and contract research organizations.
The senior unsecured term loan facility was used, in part, to refinance a three-year loan agreement between BD, Citibank, and other lenders reached last year.
The pharma company plans to use the Signatera assay to determine whether it can identify patients who will respond to immunotherapy.
The test is a targeted sequencing assay that detects mutations in the blood of non-small cell lung cancer patients to inform treatment selection.
The firm plans to use the funds to develop a five-minute point-of-care molecular diagnostic system for multiplexed infectious disease detection.
Under the deal, Novacyt's Primerdesign business will work with Applied Microarrays on the development of microarray-based diagnostic assays.
The CPMC study aims to provide participants with their genetic and non-genetic risks for disease and drug response and monitor how their behaviors change.
Arbor will provide reagents to Tataa for its courses on next-generation sequencing applications, while Tataa will distribute Arbor's products in European countries.
The firm will use the funds to advance its high-throughput single-cell analysis platform to analyze heterogeneity in cell populations for research and drug discovery.
The company said it will use the proceeds to develop new liquid biopsy tests to predict drug response in cancer patients.
The firm will sell more than 14 million shares of its common stock for $4.25 per share.
Premier is a healthcare group purchasing organization representing about 4,000 hospitals and 165,000 other providers throughout the US.
UMich's Arul Chinnaiyan plans to use the funding to develop new tools and technologies to identify biomarkers for cancer diagnosis and treatment.
An Oregon Health Authority committee issued a draft guidance to not cover NGS testing for solid tumors, which advocacy groups say will limit access to Medicaid beneficiaries.
The companies initially expect to incorporate a CDx for Incyte's pemigatinib into Foundation Medicine's existing FDA-approved assay, FoundationOne CDx.
An Australian-led team has generated a draft genome assembly of the invasive cane toad in hopes it will help in population control, the Sydney Morning Herald reports.
The New York Times reports that the US Department of Defense has implemented about half the recommendations made to improve safe handling of dangerous agents.
In PLOS this week: approach for teasing out archaic introgression in human genomes, immune transcription features in HCV infection, and more.
Stat News reports that Maryland is promoting itself to the biotech industry with a mobile billboard.